BACKGROUND:Amodiaquine (AQ) is paired with artesunate (AS) or sulfadoxine-pyrimethamine (SP) in recommended antimalarial regimens. It is unclear how readily AQ resistance will be selected with combination chemotherapy. METHODS: We collected 61 Plasmodium falciparum samples from a cohort of Ugandan children randomized for treatment with AQ-SP, AS-AQ, or artemether-lumefantrine (AL) for uncomplicated malaria. In vitro susceptibility to monodesethylamodiaquine (MDAQ) was measured with a histidine-rich protein 2-based enzyme-linked immunosorbent assay, and potential resistance-mediating polymorphisms in pfmdr1 were evaluated. RESULTS: Parasites collected from patients treated with AQ-SP or AS-AQ within the prior 12 weeks were less susceptible to MDAQ (n = 18; mean of the median inhibitory concentration [IC(50)], 62.9 nmol/L; range, 12.7-158.3 nmol/L) than were parasites from those not treated within 12 weeks (n = 43; mean IC(50), 37.5 nmol/L; range, 6.3-184.7 nmol/L; P=.009) or only from those patients in the treatment arm that did not receive AQ (n = 12; mean IC(50), 28.8 nmol/L; range, 6.3-121.8 nmol/L; P = .004). The proportion of strains with polymorphisms expected to mediate diminished response to AQ (pfmdr1 86Y and 1246Y) increased after AQ therapy, although differences were not statistically significant. CONCLUSIONS: Prior therapy selected for diminished response to MDAQ, which suggests that AQ-containing regimens may rapidly lose efficacy in Africa. The mechanism of diminished MDAQ response is not fully explained by known mutations in pfmdr1.
RCT Entities:
BACKGROUND:Amodiaquine (AQ) is paired with artesunate (AS) or sulfadoxine-pyrimethamine (SP) in recommended antimalarial regimens. It is unclear how readily AQ resistance will be selected with combination chemotherapy. METHODS: We collected 61 Plasmodium falciparum samples from a cohort of Ugandan children randomized for treatment with AQ-SP, AS-AQ, or artemether-lumefantrine (AL) for uncomplicated malaria. In vitro susceptibility to monodesethylamodiaquine (MDAQ) was measured with a histidine-rich protein 2-based enzyme-linked immunosorbent assay, and potential resistance-mediating polymorphisms in pfmdr1 were evaluated. RESULTS: Parasites collected from patients treated with AQ-SP or AS-AQ within the prior 12 weeks were less susceptible to MDAQ (n = 18; mean of the median inhibitory concentration [IC(50)], 62.9 nmol/L; range, 12.7-158.3 nmol/L) than were parasites from those not treated within 12 weeks (n = 43; mean IC(50), 37.5 nmol/L; range, 6.3-184.7 nmol/L; P=.009) or only from those patients in the treatment arm that did not receive AQ (n = 12; mean IC(50), 28.8 nmol/L; range, 6.3-121.8 nmol/L; P = .004). The proportion of strains with polymorphisms expected to mediate diminished response to AQ (pfmdr1 86Y and 1246Y) increased after AQ therapy, although differences were not statistically significant. CONCLUSIONS: Prior therapy selected for diminished response to MDAQ, which suggests that AQ-containing regimens may rapidly lose efficacy in Africa. The mechanism of diminished MDAQ response is not fully explained by known mutations in pfmdr1.
Authors: G E Childs; E F Boudreau; W K Milhous; T Wimonwattratee; N Pooyindee; L Pang; D E Davidson Journal: Am J Trop Med Hyg Date: 1989-01 Impact factor: 2.345
Authors: H L Yang; D Q Liu; Y M Yang; K G Huang; Y Dong; P F Yang; M Z Liao; C Y Zhang Journal: Southeast Asian J Trop Med Public Health Date: 1997-09 Impact factor: 0.267
Authors: G W Long; G Watt; N Sy; R L Buck; R P Sangalang; C P Ranoa Journal: Southeast Asian J Trop Med Public Health Date: 1987-06 Impact factor: 0.267
Authors: Agnes Aubouy; Justice Mayombo; Annick Keundjian; Mohamed Bakary; Jacques Le Bras; Philippe Deloron Journal: Am J Trop Med Hyg Date: 2004-09 Impact factor: 2.345
Authors: Rina P M Wong; Harin Karunajeewa; Ivo Mueller; Peter Siba; Peter A Zimmerman; Timothy M E Davis Journal: Antimicrob Agents Chemother Date: 2010-11-15 Impact factor: 5.191
Authors: Mónica Guerra; Rita Neres; Patrícia Salgueiro; Cristina Mendes; Nicolas Ndong-Mabale; Pedro Berzosa; Bruno de Sousa; Ana Paula Arez Journal: Antimicrob Agents Chemother Date: 2016-12-27 Impact factor: 5.191
Authors: Stephanie A Rasmussen; Frida G Ceja; Melissa D Conrad; Patrick K Tumwebaze; Oswald Byaruhanga; Thomas Katairo; Samuel L Nsobya; Philip J Rosenthal; Roland A Cooper Journal: Antimicrob Agents Chemother Date: 2017-11-22 Impact factor: 5.191
Authors: Patrick Tumwebaze; Melissa D Conrad; Andrew Walakira; Norbert LeClair; Oswald Byaruhanga; Christine Nakazibwe; Benjamin Kozak; Jessica Bloome; Jaffer Okiring; Abel Kakuru; Victor Bigira; James Kapisi; Jennifer Legac; Jiri Gut; Roland A Cooper; Moses R Kamya; Diane V Havlir; Grant Dorsey; Bryan Greenhouse; Samuel L Nsobya; Philip J Rosenthal Journal: Antimicrob Agents Chemother Date: 2015-03-09 Impact factor: 5.191